AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29378016
Drug: ASP9226 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP9226 (50 mg)
Trial: 24520664
Drug: L-carnitine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine + tadalafil
Trial: 24520664
Drug: Safety of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety of medication
Trial: 22847195
Drug: Vitamins (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins (1000 mg of vitamin C, 800 IU of vitamin E, and 300 mg of Coenzyme Q‐10) for 14 days
Trial: 12151908
Drug: Donepezil (DPZ)
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil (DPZ) 10 mg/day
Trial: 8665881
Drug: Neostigmine (0.036
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.036 mg kg‐1)
Trial: 30586695
Drug: Patisiran (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran (0.3 mg/kg via intravenous infusion once every 3 weeks for 18 months)
Trial: 26825829
Drug: Paclitaxel (PTX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (PTX, 175 mg/m²) plus Carboplatin (CBDCA) (TC chemotherapy)
Trial: 26825829
Drug: Docetaxel (DTX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (DTX, 60 mg/m²) plus Carboplatin (CBDCA) (DC chemotherapy)
Trial: 26825829
Drug: Both TC
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both TC and DC chemotherapy
Trial: 25902653
Drug: Meldonium (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meldonium (1 g/day intravenously for 2 weeks then orally until 1.5 months)
Trial: 22087585
Drug: 1.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g/day free plant sterols and stanols
Trial: 17367312
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg/day for 8 weeks followed by 20 mg/day for a further 8 weeks
Trial: 17367312
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/day for 8 weeks followed by 20 mg/day for a further 8 weeks
Trial: 17367312
Drug: Rosuvastatin and
RxNorm normalized name: rosuvastatin and ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin and Atorvastatin
Trial: 7922450
Drug: Growth factors
RxNorm normalized name: INVEST HEMATOLOGIC DEFICIENCIES,HEMATOPOEITIC GROWTH FACTORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth factors in combination with specialized nutrition
Trial: 3149548
Drug: Adenosine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (various doses, intra-arterial)
Trial: 26576946
Drug: Blended Motivational
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended Motivational Interviewing and Problem Solving Therapy (MI-PST)
Trial: 21039351
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at target effect-site concentrations of 2.0, 2.5, 3.0, 3.5, and 4.0 microg/ml during TCI with sufentanil (0.2 ng/ml)
Trial: 17133564
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 2 to 3 g/day with reduced CNI dose (≥50% of initial dose)
Trial: 17133564
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no MMF, CNI dose not reduced below 75% of initial dose)
Trial: 1279468
Drug: Ranitidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (50 mg 4 times a day e.v.)
Trial: 1279468
Drug: No anti
RxNorm normalized name: Cellano antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti H2 treatment (Control)
Trial: 3769898
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg meptazinol i.m.
Trial: 26482543
Drug: Doxepin hydrochloride
RxNorm normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxepin hydrochloride (6 mg) in tomato juice
Trial: 22200728
Drug: Bosentan, 125
RxNorm normalized name: Bosentan, 125 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan, 125 mg two times per day, n = 28
Trial: 18568482
Drug: Axitinib (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (administered orally twice daily until disease progression or intolerance)
Trial: 15752950
Drug: 5 mg/d
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d of oral folic acid for 4 weeks
Trial: 10342484
Drug: Therapeutic massage
RxNorm normalized name: All Body Powerful Therapeutic Massager
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic massage sessions of 10 minutes per day in combination with treatment with pressure garments
Trial: 8595539
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray, 2 sprays/nostril bid
Trial: 8595539
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray, 2 sprays/nostril qd
Trial: 8595539
Drug: Oral chlorpheniramine
RxNorm normalized name: chlorpheniramine Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chlorpheniramine maleate, 12 mg bid
Trial: 1790542
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg thrice daily)
Trial: 6111632
Drug: Propranolol (60‐120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (60‐120 mg/day)
Trial: 28453849
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) with initial efavirenz
Trial: 25784719
Drug: CDP7657 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP7657 IV (0.004-5 mg/kg)
Trial: 25784719
Drug: CDP7657 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP7657 IV (5-60 mg/kg)
Trial: 12501898
Drug: Misoprostol (1-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (1-11 tablets, vaginal route)
Trial: 9831367
Drug: IFN-alpha +
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha + Talpha1 (1 mg twice weekly)
Trial: 7716590
Drug: Meropenem 500
RxNorm normalized name: meropenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 500 mg every 8 hours
Trial: 7716590
Drug: Imipenem/cilastatin 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin 500 mg every 6 hours
Trial: 788079
Drug: Intravenous plasminogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous plasminogen
Trial: 30884961
Drug: Telephone-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based cognitive behavioral therapy (CBT)
Trial: 21666588
Drug: Cytoflavin, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin, 2 ml/kg/day, intravenously for 5 days
Trial: 21666588
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment without cytoflavin
Trial: 19299322
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba 120 mg twice daily for 12 days
Trial: 19299322
Drug: Voriconazole 200
RxNorm normalized name: voriconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole 200 mg alone
Trial: 11565630
Drug: Pagoclone 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pagoclone 0.1 mg t.d.s.
Trial: 9137213
Drug: Amiodarone, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone, 300 mg/day
Trial: 9137213
Drug: Nonantiarrhythmic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonantiarrhythmic therapy
Trial: 30818782
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day iron (800 mg of iron protein succinylate)
Trial: 27864718
Drug: 32 NaP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 NaP tablets
Trial: 27864718
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L of PEG
Trial: 23727761
Drug: Dance/movement therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance/movement therapy
Trial: 11015108
Drug: Bladder-drainage with
RxNorm normalized name: Sus scrofa urinary bladder preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder-drainage with induction immunotherapy
Trial: 11015108
Drug: Enteric-drainage with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-drainage with induction immunotherapy
Trial: 11015108
Drug: Enteric-drainage without
RxNorm normalized name: ENTERAL DRAINAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-drainage without induction immunotherapy
Trial: 26997110
Drug: Phone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phone administration preference
Trial: 22443183
Drug: Insulin dose
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dose increase (≥ 10% at week 12 and ≥ 10% at week 24)
Trial: 20139217
Drug: Delayed use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed use of antibiotics
Trial: 20139217
Drug: Antibiotic delay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic delay strategy
Trial: 11333850
Drug: Beta-carotene dissolved
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene dissolved in oil (80 microg per capsule) consumed 2 capsules/day, 7 days/week for up to 10 weeks
Trial: 2894890
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 to 40 mg once daily
Trial: 24284249
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium 20/40 mg administered via intravenous injection after admission with 12 hours intervals for six times
Trial: 24284249
Drug: Morphine 2/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 2/4 mg initially, additional morphine 2 mg as needed
Trial: 10924972
Drug: Accelerated fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated fractionation (AF) of 30 Gy in 10 daily fractions
Trial: 10924972
Drug: Accelerated hyperfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hyperfractionated (AH) radiotherapy (1.6 Gy b.i.d. to a total dose of 54.4 Gy)
Trial: 1423948
Drug: 12,500 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12,500 IU heparin s.c.
Trial: 24154666
Drug: Sertraline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline treatment (up to 200 mg/d over 10 weeks)
Trial: 18211496
Drug: Topical antimycotic
RxNorm normalized name: ANTIMYCOTICS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimycotic treatment
Trial: 16983120
Drug: Intensification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification of induction therapy with HAM (high-dose cytarabine and mitoxantrone)
Trial: 16983120
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction therapy without HAM
Trial: 11020031
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg/day
Trial: 11020031
Drug: propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol 80 mg/day
Trial: 1569652
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg ascorbic acid (placebo)
Trial: 1569652
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ascorbic acid
Trial: 11198264
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg ascorbic acid
Trial: 1569652
Drug: 2,000 mg
RxNorm normalized name: garlic 2,000 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000 mg ascorbic acid
Trial: 2857181
Drug: SPH (PAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH (PAS plus isoniazid daily for 18 months with streptomycin for the first three months)
Trial: 2857181
Drug: PH (PAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PH (PAS plus isoniazid daily for 18 months without streptomycin)
Trial: 2857181
Drug: IP (inpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP (inpatient rest in bed for six months followed by outpatient treatment)
Trial: 2857181
Drug: OP (ambulatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OP (ambulatory outpatient treatment from the start)
Trial: 2857181
Drug: J (outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: J (outpatient treatment with a plaster-of-Paris jacket for nine months)
Trial: 2857181
Drug: No J
RxNorm normalized name: Alfamino Junior Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No J (ambulatory treatment without any support)
Trial: 2857181
Drug: Additional chemotherapy
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional chemotherapy and/or operation
Trial: 2857181
Drug: Additional chemotherapy
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional chemotherapy and/or surgery
Trial: 29704010
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy (IP) after NACT and IDS
Trial: 29704010
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy (IV) after NACT and IDS
Trial: 29704010
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy (IP) after PDS
Trial: 29704010
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy (IV) after PDS
Trial: 24817084
Drug: Non-laxative preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-laxative preparation
Trial: 22745235
Drug: HAM‐RS2 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAM‐RS2 (40 g/d)
Trial: 18478213
Drug: NGF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGF (5 microg in 0.2 ml) injection into the masseter muscle
Trial: 18478213
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (0.9%, 0.2 ml) injection into the masseter muscle
Trial: 18478213
Drug: Glutamate (1
RxNorm normalized name: Glutamate (13-N)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamate (1 M, 0.2 ml) injection after 24 h
Trial: 10369259
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with ALOX5-pathway modifiers
Trial: 2203282
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg epinephrine (LE)
Trial: 2203282
Drug: 0.4 ml
RxNorm normalized name: ethanol 0.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 ml saline (L)
Trial: 9272316
Drug: Tobramycin ophthalmic
RxNorm normalized name: tobramycin ophthalmic
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin ophthalmic solution
Trial: 19809809
Drug: Fenugreek seed
RxNorm normalized name: FENUGREEK SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek seed extract (588 mg)
Trial: 19809809
Drug: Fenugreek seed
RxNorm normalized name: FENUGREEK SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek seed extract (1176 mg)
Trial: 17578980
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral controlled-release oxycodone every 12 hours from the evening before surgery until the second postoperative morning.
Trial: 17578980
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral controlled-release oxycodone
Trial: 16353064
Drug: Isosorbide-5-mononitrate (ephox-long,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (ephox-long, 50-100 mg o.d.)
Trial: 16353064
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (nitrosorbide, 10-20 mg t.i.d.)
Trial: 10468697
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg b.d. during dosing
Trial: 10468697
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg b.d. before dosing
Trial: 2079386
Drug: viloxazine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: viloxazine (400 mg per os daily)
Trial: 6998538
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin prophylaxis (5000 i.u. every 12 h for 5‐7 days) + graduated compression stockings
Trial: 25283480
Drug: Higher-dose vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose vitamin D3 (2000 IU/800 IU)
Trial: 25283480
Drug: Lower-dose vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose vitamin D3 (1000 IU/400 IU)
Trial: 19573122
Drug: Exenatide once
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide once weekly (QW)
Trial: 6140220
Drug: Propranolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (10 mg i.v.)
Trial: 2908765
Drug: Clonidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.3 mg p.o.)
Trial: 30107819
Drug: Structured, non-pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured, non-pharmacological care delivered by students of medicine, psychology and nursing, together with standard medical treatment
Trial: 25644495
Drug: Septal body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Septal body volume reduction (SBVR) with concurrent bilateral microdebrider-assisted SBVR during turbinate surgery
Trial: 22282887
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus insertion of a lumbar drain
Trial: 18065789
Drug: Antimicrobial lock
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial lock solution (ALS)
Trial: 16107989
Drug: DMAS device
RxNorm normalized name: DLin-MC3-DMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMAS device with monthly adherence counseling
Trial: 320671
Drug: Ibuprofen, 1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen, 1,800 mg/day
Trial: 320671
Drug: Aspirin, 3,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 3,600 mg/day
Trial: 31995406
Drug: Standardized antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized antihypertensive treatment (triple therapy)
Trial: 25552575
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure lowering (target SBP <140 mm Hg within 1 hour, lower limit of 130 mm Hg for treatment cessation)
Trial: 21528598
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg orally after breakfast)
Trial: 20467616
Drug: 10‐ to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐ to 16‐mm‐long implants after lateral sinus lifting with 50% anorganic bovine (Bio‐Oss) and 50% autogenous bone
Trial: 20467616
Drug: 8‐mm‐long implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8‐mm‐long implants after crestal sinus lifting with autogenous bone
Trial: 22872734
Drug: Adjuvanted recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted recombinant glycoprotein E vaccine (HZ/su; n = 45)
Trial: 22872734
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated Oka strain VZV vaccine (OKA; n = 45)
Trial: 22872734
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HZ/su and OKA administered concomitantly (n = 45)
Trial: 22872734
Drug: Adjuvanted recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted recombinant glycoprotein E vaccine (HZ/su; n = 10) in young adults
Trial: 22872734
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated Oka strain VZV vaccine (OKA; n = 10) in young adults
Trial: 16163369
Drug: Surfactant administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant administration followed by extubation to NCPAP (N=52)
Trial: 12745512
Drug: Nicotine inhaler
RxNorm normalized name: nicotine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine inhaler (NI) plus nicotine patch (NP) (15 mg nicotine/16 h) for 6 weeks, then NI plus placebo patch (PP) for 6 weeks, then NI alone for 14 weeks.